Results 41 to 50 of about 53,085 (229)

Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.

PLoS ONE, 2010
The proteasome inhibitor bortezomib represents an important advance in the treatment of multiple myeloma (MM). Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of ...
Feng Ge, Chuan-Le Xiao, Li-Jun Bi, Sheng-Ce Tao, Sheng Xiong, Xin-Feng Yin, Li-Ping Li, Chun-Hua Lu, Hai-Tao Jia, Qing-Yu He   +9 more
doaj   +1 more source

ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5

JCI Insight, 2022
The proteasome inhibitors (PIs) bortezomib and carfilzomib, which target proteasome 20S subunit beta 5 (PSMB5) in cells, are widely used in multiple myeloma (MM) treatment.
Yan Yang, Yuhan Gao, Jingcao Huang, Zhuang Yang, Hongmei Luo, Fangfang Wang, Juan Xu, Yushan Cui, Hong Ding, Zhimei Lin, Xinyu Zhai, Ying Qu, Li Zhang, Ting Liu, Lingqun Ye, Ting Niu, Yuhuan Zheng   +16 more
doaj   +1 more source

A New Recruitable E3 Ligase UHRF1 Supporting Targeted Protein Degradation: A Minimal Azide as a Recruitment Ligand

Advanced Science, EarlyView.
Targeted protein degradation is often limited by the scarcity of usable E3 ligases. Herein, we report the first small‐molecule GPX4 degraders that incorporate either electrophilic warheads or a minimal azide group as an E3 recruitment ligand. The azide‐based degrader DK‐5070 effectively drives potent GPX4 degradation; mechanistic studies reveal that ...
Zehong Lin, Kang Duan, Rui Wan, Tao Jiang, Jinzhe Wei, Miao Sun, Mariia A. Skryl'nikova, Maxim A. Gureev, Zhi‐Min Zhang, Zhang Zhang, Ke Ding, Nan Ma, Tongzheng Liu, Yi Tan, Zhengqiu Li   +14 more
wiley   +1 more source

Antifungal effects and potential mechanism of bortezomib in combination with fluconazole against <i>Candida albicans</i>. [PDF]

Front Cell Infect Microbiol
Wang Y, Wang B, Li J, Ma S, Liu P, Teng Z, Zou H, Cong R, Sui X, Li X, Cui Y.   +10 more
europepmc   +3 more sources

Bridging Chemical Literature and Molecular Graphs: LLM‐Augmented Enantioselectivity Prediction for Iridium‐Catalyzed Asymmetric C–H Borylation

Advanced Science, EarlyView.
A machine‐learning framework for asymmetric C–H borylation bridges multi‐entity 3D molecular graphs and chemical literature. Atom‐resolved mechanistic annotations extracted by large language models augment three‐component graph encoding of catalyst, substrate, and product. The model predicts enantioselectivity with high accuracy on unseen scaffolds and
Zhe Wang, Baohua Zhang, Yi Isaac Yang, Yuan Yao, Yinwu Li   +4 more
wiley   +1 more source

Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity

Case Reports in Cardiology, 2016
Bortezomib is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. Traditionally, bortezomib was thought to have little cardiovascular toxicity; however, there is increasing evidence that bortezomib can lead to cardiac ...
Sachin Diwadkar, Aarti A. Patel, Michael G. Fradley   +2 more
doaj   +1 more source

Mitochondrial Localization of Cx26 Promotes Colorectal Cancer Malignancy and Exposes a Fatal Vulnerability to Drug Targeting

Advanced Science, EarlyView.
Mitochondrial localization of Cx26 emerges as a double‐edged sword in colorectal cancer. PIMT‐mediated methylation of Cx26 promotes its mitochondrial localization and stability. Mitochondrial Cx26 then facilitates ER‐mitochondria communication and Ca2+ signaling, thereby promoting metastatic progression. Bortezomib exploits this malignant adaptation by
Jie Wang, Lu Chen, Jia Qin, Xiaoning Wang, Sunlan Ye, Ning An, Mei Bai, Yan Shen, Xuefeng Wu, Qiang Xu   +9 more
wiley   +1 more source

Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma

Case Reports in Hematology, 2016
Bortezomib is a first-generation proteasome inhibitor used in the treatment of multiple myeloma (MM). A few reports have linked bortezomib exposure with the development of thrombotic microangiopathy (TMA).
Jan Van Keer, Michel Delforge, Daan Dierickx, Kathelijne Peerlinck, Evelyne Lerut, Ben Sprangers   +5 more
doaj   +1 more source

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy

Experimental Hematology & Oncology, 2012
Peripheral neuropathy (PN) is one of the most common side effects of bortezomib therapy. The majority of bortezomib-related PN is a sensory neuropathy of mild to moderate degree, and is reversible after dose reduction or discontinuation.
Jeter Ashley, Kang Yubin
doaj   +1 more source

Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. [PDF]

PLoS ONE, 2012
Bortezomib, a novel proteasome inhibitor approved for the treatment of cancer in adults, has recently been introduced in pediatric clinical trials. Any tissue-specific side effects on bone development have to our knowledge not yet been explored.
Emma Eriksson, Farasat Zaman, Dionisios Chrysis, Henrik Wehtje, Terhi J Heino, Lars Sävendahl   +5 more
doaj   +1 more source